Incorrect password
evipedia.ai Suggest Edit

Trans-Resveratrol for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Resveratrol, 3,5,4’-Trihydroxystilbene, trans-3,5,4’-Trihydroxystilbene

Motivation

Trans-resveratrol is a plant-derived stilbene found naturally in grape skins, red wine, berries, and Japanese knotweed. It became one of the most prominent compounds in longevity research after early laboratory work suggested it could mimic some of the molecular effects of caloric restriction by activating cellular stress-response pathways linked to aging and metabolic health.

Public interest accelerated through the so-called French paradox — observations linking moderate red wine consumption with lower cardiovascular disease — and through high-profile scientist-entrepreneurs who incorporated trans-resveratrol into their personal longevity protocols. However, decades of human trials have produced more modest, population-specific results than the laboratory work implied, and a recent comprehensive analysis has questioned whether trans-resveratrol meaningfully activates its flagship target pathway at doses humans can practically consume. Bioavailability — the proportion of an oral dose that actually reaches circulation — has remained the central limiting factor.

This review examines the current human evidence for trans-resveratrol, the populations and conditions where benefits are most consistent, and the unresolved questions that distinguish hype from substantiated effect.

Benefits - Risks - Protocol - Conclusion

A curated selection of accessible overviews covering trans-resveratrol’s proposed mechanisms, the human clinical evidence, and expert perspectives on supplementation.

  • Resveratrol - Rhonda Patrick

    Dedicated topic page summarizing trans-resveratrol’s proposed mechanisms (including SIRT1 activation, AMPK signaling, and caloric-restriction mimicry), dietary sources, and the human evidence base. Discusses bioavailability constraints, the divergence between in vitro and clinical findings, and dosing considerations.

  • Resveratrol and Metabolic Health — Failure of Resveratrol to Improve Metabolic Health Is Another Nail in the Coffin - Peter Attia

    Skeptical, evidence-based assessment of why trans-resveratrol supplementation has not delivered the metabolic health effects predicted by mechanism-of-action work. Examines bioavailability, the gap between animal and human results, and resveratrol’s limited clinical utility relative to other interventions.

  • AMA #12 — Thoughts on Longevity Supplements: NR, NMN, Resveratrol, and Others - Andrew Huberman

    Candid discussion of trans-resveratrol’s place in the longevity-supplement landscape, noting the limited direct evidence for lifespan extension in humans. Places trans-resveratrol alongside other NAD-related and polyphenol interventions, and explains the reasoning behind preferring whole-food polyphenol sources for some users.

  • How to Slow Aging and Increase Healthspan: Interview with Dr. David Sinclair - Chris Kresser

    Long-form interview presenting David Sinclair’s case for trans-resveratrol as part of a sirtuin-activating, NAD+-supporting longevity stack. Covers historical context, the caloric-restriction-mimetic hypothesis, and Sinclair’s personal protocol of approximately 1 g/day combined with nicotinamide mononucleotide.

  • Is Resveratrol Still a Healthy Aging Supplement? - Life Extension Magazine

    September 2024 review revisiting whether trans-resveratrol remains a defensible aging supplement in light of recent clinical evidence. Examines micronized and other enhanced-bioavailability formulations and their reported absorption advantages, and reassesses trans-resveratrol’s position relative to other polyphenols and NAD+ modulators.

Grokipedia

Resveratrol

Encyclopedia-style overview of resveratrol covering its chemistry as a stilbene polyphenol, dietary sources, proposed biological mechanisms (including SIRT1 and AMPK activation), the trans/cis isomer distinction, and the current state of human clinical evidence with attention to bioavailability constraints.

Examine

Resveratrol

Comprehensive supplement page covering trans-resveratrol’s effects on cardiovascular, metabolic, inflammatory, and aging-related outcomes. Provides structured summaries of clinical-trial evidence, dosing, bioavailability, and safety — among the most thorough independent supplement references available.

ConsumerLab

Resveratrol Supplements Review

Independent testing review of trans-resveratrol supplements, examining product purity, label accuracy, and the prevalence of standard versus enhanced-bioavailability formulations (micronized, phytosome). Includes top picks based on quality testing.

Systematic Reviews

A summary of recent systematic reviews and meta-analyses evaluating trans-resveratrol supplementation in humans, drawn from PubMed.

Mechanism of Action

Trans-resveratrol is proposed to act through several overlapping pathways, although the clinical relevance of each at human-achievable plasma concentrations is debated.

The most prominent proposed mechanism is activation of SIRT1, a NAD+ (nicotinamide adenine dinucleotide, a coenzyme required for sirtuin activity)-dependent deacetylase that regulates stress resistance, mitochondrial function, and metabolic signalling. This mechanism underlies the “caloric-restriction mimetic” hypothesis — the idea that trans-resveratrol partially reproduces the molecular effects of reduced caloric intake. The Mansouri et al. (2025) GRADE-assessed meta-analysis questions whether oral trans-resveratrol achieves meaningful SIRT1 activation in humans at conventional supplemental doses, suggesting the in vitro and animal effects may not translate at the plasma concentrations supplementation actually produces.

Trans-resveratrol also activates AMPK (AMP-activated protein kinase, a cellular energy sensor), which suppresses mTOR (mechanistic target of rapamycin, a growth and aging signalling hub) and promotes mitochondrial biogenesis. AMPK activation is invoked to explain proposed metabolic and longevity effects.

As a polyphenol, trans-resveratrol scavenges reactive oxygen species and chelates transition-metal ions, contributing to antioxidant activity. It inhibits NF-κB (nuclear factor kappa B, a master inflammatory transcription factor), reducing production of pro-inflammatory cytokines including IL-6 (interleukin-6) and TNF-α (tumor necrosis factor alpha), and suppresses COX-2 (cyclooxygenase-2, an inflammatory prostaglandin enzyme).

Trans-resveratrol enhances eNOS (endothelial nitric oxide synthase) activity, raising nitric oxide bioavailability in the vascular endothelium and supporting flexibility and flow — the mechanism most directly linked to its consistently observed flow-mediated dilation effects in clinical trials.

Pharmacologically, trans-resveratrol has very low oral bioavailability (commonly cited as approximately 1–2%) due to extensive first-pass sulfation and glucuronidation in the gut wall and liver. Its plasma half-life of unconjugated trans-resveratrol is short (~1–3 hours), although sulfate and glucuronide metabolites circulate longer and may contribute biologically. It is metabolised primarily by Phase II enzymes (sulfotransferases and UGTs [UDP-glucuronosyltransferases, conjugating enzymes that inactivate many polyphenols and drugs]), with minor cytochrome P450 (CYP, a family of liver enzymes) involvement.

Two isomers exist: trans-resveratrol (the predominant biologically active form found in plants and quality supplements) and cis-resveratrol (which can form on UV exposure and has minimal biological activity).

Historical Context & Evolution

Trans-resveratrol was first isolated in 1940 from Veratrum grandiflorum, but it remained a minor curiosity until the 1990s, when it was identified as a constituent of red wine and connected to the so-called “French paradox” — the epidemiologic observation that French populations consuming red wine appeared to have lower cardiovascular disease rates despite high saturated fat intake. The hypothesis that trans-resveratrol drove this protection generated substantial popular and research interest, despite the fact that the doses used in laboratory studies were far higher than achievable through wine consumption.

In the early 2000s, work led by David Sinclair and colleagues reported that trans-resveratrol activated Sir2 (the yeast SIRT1 homolog) and extended lifespan in yeast and in several short-lived model organisms. Subsequent rodent studies suggested benefits for metabolic health, particularly in animals on high-fat diets. These results launched trans-resveratrol as the flagship “sirtuin-activating compound” and inspired commercial interest, including the formation and acquisition of biotech companies developing sirtuin activators.

Through the 2010s, large numbers of small human trials examined trans-resveratrol across cardiovascular, metabolic, neurological, and oncology endpoints. The pattern that emerged was inconsistent: some trials in metabolically compromised populations showed clear benefits for glycemic control and endothelial function, while trials in metabolically healthy participants showed minimal effects. The scale of effect repeatedly fell short of what mechanism-of-action work in cells and animals predicted, with bioavailability and rapid Phase II metabolism increasingly recognised as bottlenecks.

The Mansouri et al. (2025) GRADE-assessed meta-analysis represents a more recent inflection point, directly addressing whether oral trans-resveratrol at typical supplemental doses meaningfully activates SIRT1 in humans. Its findings — questioning that activation at human-achievable concentrations — challenge the foundational mechanistic premise that has underpinned much of the longevity case for trans-resveratrol. This ongoing debate is unresolved: proponents argue that enhanced-bioavailability formulations and combination strategies may yet deliver the molecular effects observed in laboratory work, while skeptics view the clinical translation gap as evidence that the original hypothesis was overstated. Both positions remain in active discussion in the field.

Expected Benefits

Medium 🟩 🟩

Endothelial Function Improvement

Mohammadipoor et al. (2022) reported in a meta-analysis of 17 RCTs that trans-resveratrol supplementation significantly improved endothelial function, measured by flow-mediated dilation (FMD), and reduced ICAM-1, a marker of endothelial inflammation. This is the most consistently replicated clinical benefit across the resveratrol literature, supported mechanistically by enhanced eNOS activity and nitric oxide bioavailability. Effects appear larger in populations with baseline endothelial dysfunction (metabolic syndrome, type 2 diabetes, coronary disease).

Magnitude: Pooled FMD improvement of approximately +1.4 percentage points; ICAM-1 reduction of approximately −7 ng/mL across studies. Effects most evident in metabolically compromised populations.

Glycemic Control in Type 2 Diabetes & Metabolic Disease

Delpino & Figueiredo (2021) demonstrated in a meta-analysis of 30 clinical studies that trans-resveratrol supplementation significantly reduced fasting glucose, HbA1c, and insulin resistance in participants with type 2 diabetes or metabolic disorder, but with smaller or absent effects in metabolically healthy adults. Effects were dose-dependent, with greater benefit in studies using ≥150–250 mg/day for ≥8 weeks. This benefit profile reinforces that trans-resveratrol’s clinically meaningful glycemic effects are population-specific.

Magnitude: Pooled standardized mean difference (SMD, a unit-free effect-size measure) of approximately −0.85 for fasting glucose, −0.64 for HbA1c, and −0.34 for insulin resistance, observed primarily in diabetic and metabolic-disease subgroups.

Low 🟩

Systemic Inflammation Reduction (CRP)

Gorabi et al. (2021) found in an updated meta-analysis that trans-resveratrol supplementation produced statistically significant reductions in circulating C-reactive protein (CRP), with the largest effects in participants with chronic inflammatory or metabolic disease. Effects in healthy adults were small and inconsistent, and pooled estimates were sensitive to dose, duration, and population. Other inflammatory markers (TNF-α, IL-6) showed less consistent results across separate meta-analyses.

Magnitude: Pooled CRP reduction on the order of 0.2–0.5 mg/L in mixed populations, with larger reductions in inflammatory subgroups; effect sizes vary substantially across reviews.

Blood Pressure Reduction (Subgroup-Dependent)

Fogacci et al. (2019) meta-analysed 17 RCTs and found no significant overall effect of trans-resveratrol on systolic or diastolic blood pressure. However, subgroup analyses showed significant systolic reductions at doses ≥300 mg/day and in participants with diabetes. Blood pressure effects therefore appear restricted to higher doses or specific populations rather than universal.

Magnitude: No significant effect overall; pooled systolic reduction of approximately 4–5 mmHg in subgroups receiving ≥300 mg/day or with diabetes.

Speculative 🟨

Anti-Cancer Effects ⚠️ Conflicted

Trans-resveratrol shows broad in vitro anti-cancer activity across many tumour cell lines, with documented effects on proliferation, apoptosis, angiogenesis, and inflammatory signalling. Animal models show variable tumour-growth inhibition. Human evidence remains limited: small pilot trials in colorectal and breast settings have shown signals on tissue biomarkers but no demonstrated clinical outcome benefit. The gap between extensive preclinical promise and limited human translation is the defining feature of this domain.

Neuroprotection & Cognitive Function ⚠️ Conflicted

Several small trials in mild cognitive impairment and Alzheimer’s disease have reported effects on cerebrospinal fluid amyloid-beta (a hallmark Alzheimer’s marker) and modest cognitive endpoints with trans-resveratrol supplementation, while other trials have shown no clear benefit. Mechanistic plausibility is supported by SIRT1, AMPK, and anti-inflammatory pathway work, but human results are inconsistent and trials are generally small. The Mansouri et al. (2025) finding on SIRT1 activation adds further uncertainty about the mechanistic premise underlying these trials.

Lifespan & Healthspan Extension ⚠️ Conflicted

No human studies have demonstrated lifespan or all-cause-mortality benefits from trans-resveratrol supplementation. The lifespan-extension findings in yeast and short-lived invertebrates have not consistently replicated in mammalian models, and the Mansouri et al. (2025) GRADE-assessed meta-analysis directly questions whether the proposed primary mechanism (SIRT1 activation) operates at human-achievable plasma concentrations. Proponents argue enhanced-bioavailability formulations may still deliver the predicted effects; this remains unresolved in human data.

Exercise Adaptation Effects ⚠️ Conflicted

Reports on trans-resveratrol’s interaction with exercise training are mixed. Some studies in older adults have suggested that high-dose trans-resveratrol may blunt the cardiorespiratory adaptations to endurance training (e.g., maximal oxygen uptake, VO2max — peak oxygen consumption during exhaustive exercise), potentially by interfering with redox-mediated training signals. Other trials have reported neutral or favourable effects on performance and recovery. The conflict is unresolved and represents a meaningful uncertainty for physically active users at higher doses.

Benefit-Modifying Factors

  • Bioavailability formulation: Standard trans-resveratrol has approximately 1–2% oral bioavailability due to rapid Phase II metabolism. Micronized particles, nano-formulations, and phytosome (phospholipid-complex) formulations report substantially improved absorption (in some cases 5–10-fold). The formulation chosen meaningfully alters whether biologically relevant plasma concentrations are achieved.

  • Co-administration with food and absorption enhancers: Taking trans-resveratrol with a fat-containing meal increases absorption. Co-administration with piperine (the active component of black pepper, an inhibitor of glucuronidation and select CYPs) has been used in some protocols to reduce first-pass metabolism, although robust pharmacokinetic confirmation in humans remains limited.

  • Metabolic status (baseline biomarkers): Benefits for glycemic control, endothelial function, and inflammation are most consistent in adults with type 2 diabetes, metabolic syndrome, or established endothelial dysfunction. Adults with normal fasting glucose, normal blood pressure, and unimpaired endothelial function show smaller and less consistent responses.

  • Age: Older adults (60+), who more often present with the metabolic and vascular phenotypes that respond best to trans-resveratrol, are over-represented in trials showing benefit. Younger metabolically healthy adults are under-represented in positive subgroup analyses.

  • Pre-existing health conditions: Established cardiovascular disease, type 2 diabetes, metabolic syndrome, and chronic inflammatory conditions are the contexts in which the benefit signal is strongest.

  • Genetic polymorphisms: Variants in UGT1A1 and other UGT family enzymes (which conjugate trans-resveratrol), SULT1A1 (sulfotransferase 1A1, which sulfates trans-resveratrol), and COMT (catechol-O-methyltransferase, which metabolises catecholamine and some polyphenol substrates) may modify circulating trans-resveratrol exposure. These have not been formally validated as clinically actionable in supplementation trials.

  • Sex-based differences: No robust, replicated sex-based differences in efficacy have been established. Many trials have enrolled mixed populations without prespecified sex-stratified analyses, leaving this question underexplored rather than answered.

Potential Risks & Side Effects

Low 🟥

Gastrointestinal Discomfort

Diarrhoea, nausea, abdominal cramping, and flatulence have been reported, primarily at doses >1 g/day. Trials at 150–500 mg/day generally report adverse-event profiles comparable to placebo. Symptoms are typically mild, dose-related, and self-limiting on dose reduction or discontinuation; capsule volume and excipients may contribute at the high end of the dose range.

Magnitude: Comparable to placebo at ≤500 mg/day; clearly increased frequency above ~1 g/day but generally mild and reversible.

Drug Interaction Potential via CYP & Phase II Enzymes

In vitro work shows that trans-resveratrol can inhibit several drug-metabolising enzymes including CYP3A4 (cytochrome P450 3A4, which metabolises approximately half of marketed drugs), CYP1A2 (cytochrome P450 1A2, which metabolises caffeine and several drugs), CYP2D6 (cytochrome P450 2D6, which metabolises many psychiatric and cardiovascular drugs), and certain UGTs and sulfotransferases. Clinical pharmacokinetic studies in humans have shown more modest interactions, but the potential is real, particularly with high doses and combinations of polyphenols. Trans-resveratrol also displays mild antiplatelet activity, which can be additive with anticoagulants and antiplatelet drugs.

Magnitude: Clinically relevant interactions are plausible but inconsistently demonstrated at typical supplemental doses; risk is greatest with very high doses, multi-polyphenol stacks, narrow-therapeutic-index drugs, and concomitant antiplatelet/anticoagulant therapy.

Speculative 🟨

Possible Blunting of Endurance Training Adaptations ⚠️ Conflicted

Some controlled studies in older adults have reported that high-dose trans-resveratrol may attenuate the gains in cardiorespiratory fitness (VO2max) and certain vascular adaptations elicited by endurance training, plausibly by suppressing redox- and inflammation-mediated signalling that contributes to training adaptation. Other trials have reported neutral or favourable effects on training outcomes. The clinical importance for adults at typical supplemental doses (≤500 mg/day) is unresolved, and the effect appears more relevant at higher doses (≥1 g/day) and with high-volume endurance training.

Estrogenic / Anti-Estrogenic Activity ⚠️ Conflicted

Trans-resveratrol exhibits selective estrogen-receptor-modulator-like properties in vitro, with both agonist and antagonist effects depending on tissue, receptor subtype, and concentration. This raises theoretical concerns for adults with hormone-sensitive cancers (breast, endometrial, ovarian). Clinical evidence of harm in humans has not been established, and laboratory work has shown some anti-tumour activity in hormone-driven models, but uncertainty remains and the conservative approach is to avoid use in this population.

Hepatic Enzyme Elevation at High Doses

Mild, reversible elevations in transaminases (ALT [alanine aminotransferase, a liver enzyme], AST [aspartate aminotransferase, a liver enzyme]) have been described in a minority of participants in high-dose trials (1.5–3 g/day), with normalisation on discontinuation. The signal at typical supplemental doses (≤500 mg/day) is not consistently observed.

Renal Adverse Events in Specific Populations

A small number of older adults with multiple myeloma in a clinical trial of an investigational micronized trans-resveratrol formulation experienced renal adverse events, leading to early termination of that trial. The relevance to general supplementation in healthier populations is unclear, but caution in adults with pre-existing renal impairment or multiple myeloma is reasonable.

Risk-Modifying Factors

  • Concurrent medications: Adults taking anticoagulants (warfarin, heparin), antiplatelet drugs (aspirin, clopidogrel), narrow-therapeutic-index CYP3A4 substrates (e.g., tacrolimus, cyclosporine, certain statins), or CYP1A2/CYP2D6 substrates should review combinations carefully because of additive bleeding risk and theoretical exposure changes.

  • Pre-existing health conditions: Adults with hormone-sensitive cancers, advanced renal impairment, multiple myeloma, severe liver disease, or active bleeding disorders warrant additional caution. Trans-resveratrol’s antiplatelet activity argues for discontinuation 1–2 weeks before elective surgery.

  • Iron metabolism disorders: Trans-resveratrol chelates iron in vitro; the clinical relevance for adults with hereditary hemochromatosis or chronic iron overload is unestablished, but separate dosing from iron supplements is prudent.

  • Genetic polymorphisms: Variants in UGT1A1, SULT1A1, and CYP enzymes can theoretically alter trans-resveratrol exposure and interaction risk. These have not been formally validated as actionable in clinical decision-making.

  • Sex-based differences: No replicated sex-based differences in safety have been demonstrated. Pregnancy and lactation are reasonable contraindications because of insufficient data.

  • Age: Older adults may have reduced hepatic and renal clearance and more frequent polypharmacy, increasing interaction and adverse-event risk relative to younger adults; this argues for conservative dosing.

  • Baseline biomarkers: Adults with elevated baseline liver enzymes or impaired renal function should establish pre-supplementation values; high-dose protocols (>500 mg/day) are best avoided or monitored in these groups.

  • Exercise status: Endurance-trained adults who care about maximising cardiorespiratory adaptations should be aware of the unresolved adaptation-blunting signal, and may prefer lower doses (≤500 mg/day) or to time dosing away from the immediate training window.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs (warfarin, heparin, aspirin, clopidogrel, dabigatran, rivaroxaban): Caution; additive bleeding risk through trans-resveratrol’s mild antiplatelet activity. Monitor INR (international normalized ratio, a measure of clotting time used for warfarin) more closely if combined.

  • CYP3A4-metabolised drugs (statins such as atorvastatin and simvastatin, calcium channel blockers such as amlodipine, immunosuppressants such as cyclosporine and tacrolimus, certain benzodiazepines): Caution; potential exposure increase via CYP3A4 inhibition. Clinical impact is greatest for narrow-therapeutic-index agents.

  • CYP1A2-metabolised drugs (caffeine, theophylline, tizanidine, clozapine): Caution; potential exposure increase via CYP1A2 inhibition, with greatest practical relevance for theophylline and tizanidine.

  • CYP2D6-metabolised drugs (many antidepressants and antiarrhythmics, e.g., metoprolol, paroxetine): Caution; theoretical exposure changes; clinical evidence at supplemental doses is limited.

  • Antihypertensive medications (ACE inhibitors [angiotensin-converting enzyme inhibitors, e.g., lisinopril, ramipril], ARBs [angiotensin receptor blockers, e.g., losartan, valsartan], calcium channel blockers, diuretics): Monitor; additive blood-pressure-lowering risk, particularly at trans-resveratrol doses ≥300 mg/day.

  • Antidiabetic medications (metformin, sulfonylureas, insulin, SGLT2 [sodium-glucose cotransporter 2] inhibitors, GLP-1 [glucagon-like peptide-1] receptor agonists): Monitor; additive glucose-lowering effects in adults with diabetes; check fingerstick glucose more frequently when initiating trans-resveratrol.

  • Other polyphenol supplements (quercetin, curcumin, EGCG [epigallocatechin gallate, the principal polyphenol in green tea]): Caution; potential additive CYP and Phase II enzyme inhibition at high combined doses, with less predictable effects on co-administered medications.

  • Iron supplements: Separate dosing by ≥2 hours; trans-resveratrol can chelate iron and reduce absorption.

  • NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside): Often co-administered in longevity-stack protocols on the rationale that trans-resveratrol activates SIRT1 (which requires NAD+) and that NMN/NR raise NAD+ availability. The pharmacokinetic and clinical-outcome support for this synergy is limited, and the strategy remains experimental.

  • Populations to avoid trans-resveratrol unless specifically supervised: pregnancy or lactation (insufficient safety data; absolute contraindication during pregnancy); active bleeding disorders or use of anticoagulant therapy (contraindication unless physician-supervised); hormone-sensitive cancers (caution; consider avoidance pending personalised assessment); recent or planned surgery (discontinue ≥1–2 weeks pre-procedure); advanced renal impairment (eGFR [estimated glomerular filtration rate, a kidney-function index] <30 mL/min/1.73 m²) or multiple myeloma (caution given the renal-adverse-event signal in a high-dose trial in that population); decompensated liver disease (Child-Pugh Class C or equivalent).

Risk Mitigation Strategies

  • Choose enhanced-bioavailability formulations to limit dose load: prioritise micronized, nano-formulated, or phytosome trans-resveratrol over standard powder, so that lower oral doses can deliver target plasma concentrations and reduce GI and interaction risk associated with very high doses.

  • Start at a conservative dose and titrate: initiate at 100–250 mg/day for 2 weeks to assess tolerance before considering higher doses; this addresses GI discomfort and allows detection of drug-interaction signals.

  • Avoid very high doses (>1 g/day) outside supervised settings: addresses the GI, hepatic-enzyme-elevation, and renal-adverse-event signals, and the more pronounced exercise-adaptation-blunting signal at high doses.

  • Take with a fat-containing meal: improves absorption and may reduce GI side effects compared with empty-stomach dosing.

  • Review medication list for interaction-prone agents before starting: check for warfarin or other anticoagulants/antiplatelet drugs, narrow-therapeutic-index CYP3A4 substrates, theophylline/tizanidine, and antihypertensive/antidiabetic regimens, to address bleeding-risk and pharmacokinetic-interaction potential.

  • Separate from iron and other mineral supplements by ≥2 hours: addresses the iron-chelation absorption interaction and similar cation-binding interactions.

  • Monitor blood pressure when combining with antihypertensives, especially at ≥300 mg/day: addresses additive blood-pressure-lowering risk identified in the Fogacci et al. (2019) subgroup analyses.

  • Monitor fasting glucose when combining with antidiabetic drugs: addresses additive glucose-lowering risk in adults with diabetes already on therapy.

  • Discontinue 1–2 weeks before elective surgery: addresses additive bleeding risk from antiplatelet activity.

  • Consider liver-enzyme monitoring at doses >500 mg/day: baseline ALT/AST and follow-up at 8–12 weeks, then periodically; addresses the high-dose hepatic-enzyme-elevation signal.

  • For endurance-trained adults, prefer ≤500 mg/day and consider non-training-day or post-session timing: addresses the unresolved adaptation-blunting signal at higher doses.

  • Avoid in pregnancy, lactation, hormone-sensitive cancers (without specialist guidance), advanced renal impairment, and multiple myeloma: addresses populations with insufficient safety data or specific adverse-event signals.

Therapeutic Protocol

The protocol described below is informed by the human trial literature and by clinicians who use trans-resveratrol for cardiometabolic and longevity-oriented purposes. It is presented descriptively, not as guidance.

  • Mainstream cardiometabolic / endothelial-focused protocol: 150–500 mg/day of trans-resveratrol, taken once daily with a fat-containing meal, typically using an enhanced-bioavailability formulation (micronized, nano, or phytosome). This dose range corresponds to most positive trials for endothelial function, glycemic control in diabetes, and CRP reduction, including the Mohammadipoor et al. (2022), Delpino & Figueiredo (2021), and Gorabi et al. (2021) meta-analyses. Practitioners associated with cardiology- and metabolic-medicine-oriented integrative practice tend to favour this range.

  • High-dose longevity-stack protocol: approximately 1 g/day of trans-resveratrol, often co-administered with NMN and other longevity supplements. This pattern is most prominently associated with David Sinclair’s published descriptions of his personal protocol and with practitioners influenced by his work. It exceeds the dose range used in most controlled clinical trials, has not been validated for outcome benefit at scale, and increases risk of GI, hepatic, drug-interaction, and adaptation-blunting effects.

  • Best time of day: with the largest daily fat-containing meal to optimise absorption. There is no compelling evidence for a specific circadian timing benefit in humans.

  • Half-life and dosing pattern: unconjugated trans-resveratrol has a plasma half-life of approximately 1–3 hours; sulfate and glucuronide metabolites circulate longer. For doses >500 mg/day, splitting into morning and evening with meals may produce more stable plasma exposure than a single daily dose.

  • Single vs. split dosing: once daily is appropriate for ≤500 mg/day; split dosing is plausible for higher daily totals, although direct comparative trials are limited.

  • Genetic considerations: no validated pharmacogenomic dosing guidance exists. UGT1A1, SULT1A1, and CYP variants may influence individual exposure, but no clinical algorithm uses these for trans-resveratrol dosing.

  • Sex-based considerations: dosing is not sex-stratified in the published trial literature, and no clear evidence supports different doses for men and women.

  • Age considerations: older adults (60+) are the population in which trial benefits are most consistent for endothelial and metabolic endpoints; conservative dosing (≤500 mg/day) is reasonable given more frequent polypharmacy. Adults at the older end of the target audience should weigh interaction risk against expected benefit magnitude.

  • Baseline biomarker considerations: adults with baseline endothelial dysfunction (e.g., low FMD), prediabetes/diabetes, or elevated CRP have the most favourable benefit-to-evidence profile and the clearest rationale for a defined trial period.

  • Pre-existing condition considerations: adults with type 2 diabetes, metabolic syndrome, or established coronary disease have stronger trial-derived support for benefit than metabolically healthy adults; the latter should expect smaller effect sizes from any defined protocol.

Discontinuation & Cycling

Trans-resveratrol is typically used on an ongoing basis for cardiometabolic and longevity-oriented purposes rather than in defined cycles. There is no documented withdrawal syndrome, dependence, or rebound effect on discontinuation. Pharmacological effects on blood pressure, endothelial function, and metabolic markers would be expected to wane within days to weeks of stopping, in line with the short half-life of the unconjugated compound. Long-term safety data extending beyond 12 months of continuous use are limited. Some practitioners use periodic breaks (e.g., a 2–4-week break after 12 weeks of use) on precautionary grounds, but this is not evidence-based; tapering is unnecessary given the absence of withdrawal effects.

Sourcing and Quality

  • Trans isomer specification: select products that specify “trans-resveratrol” content, ideally ≥98% trans by HPLC (high-performance liquid chromatography, an analytical chemistry technique). The cis isomer has minimal biological activity, and trans-to-cis conversion can occur with UV exposure or improper storage.

  • Source botanical: common sources include Polygonum cuspidatum (Japanese knotweed) extract and grape skin/seed extract. Japanese knotweed extracts typically achieve higher resveratrol concentrations and are the more common supplement source; grape-derived products may include additional polyphenols but generally lower resveratrol content per capsule.

  • Bioavailability formulation: prefer micronized, nano-formulated, or phytosome (phospholipid-complex) products over standard powder where evidence-based plasma exposure matters; standard products are inexpensive but absorption is poor.

  • Third-party testing: prefer products with USP, NSF, or ConsumerLab certification, given documented variability in label accuracy across the resveratrol supplement category.

  • Purity considerations: ensure absence of significant emodin (a laxative anthraquinone present in Japanese knotweed) at clinically relevant levels, which can drive GI side effects.

  • Reputable brands: Life Extension Optimized Resveratrol, Thorne ResveraCel, Pure Encapsulations Resveratrol VESIsorb, NOW Foods Trans-Resveratrol, and Jarrow Formulas Resveratrol are among brands with established third-party-testing reputations; this listing is illustrative, not exhaustive.

  • Storage: store away from direct light, heat, and humidity; trans-resveratrol can isomerise to the inactive cis form on prolonged UV exposure.

Practical Considerations

  • Time to effect: endothelial and inflammatory markers typically respond over 4–12 weeks of consistent use; glycemic effects in adults with type 2 diabetes are generally observed by 8–12 weeks. Subjective effects within the first 1–2 weeks should be interpreted cautiously and may reflect placebo or co-interventions.

  • Common pitfalls: using standard low-bioavailability powder at “label dose” without expecting the corresponding low plasma exposure; expecting healthy-population benefits comparable to those seen in metabolically compromised trial cohorts; high-dose ≈1 g/day longevity-stack use without weighing the GI, hepatic, and adaptation-blunting trade-offs; overlooking interaction risk with anticoagulants, narrow-therapeutic-index CYP3A4 substrates, and antidiabetic regimens; and using untested combination stacks (e.g., trans-resveratrol + NMN + multiple polyphenols) without considering additive interaction risk.

  • Regulatory status: in the United States, trans-resveratrol is sold as a dietary supplement and is not approved as a drug for any indication. It carries Generally Recognized As Safe (GRAS) status for some food applications. In the European Union, trans-resveratrol from Polygonum cuspidatum has Novel Food authorisation for use in food supplements within specified limits.

  • Cost and accessibility: standard trans-resveratrol is widely available and inexpensive (commonly USD 10–25/month). Enhanced-bioavailability formulations (micronized, phytosome) are more expensive (commonly USD 30–80/month) but often deliver more meaningful plasma exposure per dollar than higher-dose standard powder.

Interaction with Foundational Habits

  • Sleep: Direct effect on sleep architecture is limited and the direction is plausibly neutral. Trans-resveratrol does not produce sedation or stimulation in standard doses, and there is no consistent human evidence that it improves or worsens sleep duration or quality. Mechanistically, trans-resveratrol can modulate clock-gene signalling in vitro, but this has not translated into demonstrated clinical sleep effects. Practical timing: dosing with the largest fat-containing meal of the day is the dominant consideration; choosing morning vs. evening primarily reflects convenience.

  • Nutrition: Direction is potentiating with respect to absorption when co-administered with dietary fat, and indirect with respect to overall metabolic effect. Trans-resveratrol absorption is improved by fat-containing meals because of micellar incorporation. Dietary intake of trans-resveratrol from food (red wine 0.3–6 mg/glass; grapes; berries; peanuts) is small relative to supplemental doses. A polyphenol-rich diet (other stilbenes, flavonoids) may provide complementary anti-inflammatory and vascular effects, though additive CYP and Phase II inhibition becomes a consideration with high combined polyphenol intakes. Trans-resveratrol can reduce iron absorption, supporting separation from iron-rich meals or iron supplements by ≥2 hours in adults concerned about iron status.

  • Exercise: Direction is potentially blunting in some studies, neutral in others — the relationship is unresolved and dose-dependent. The blunting signal for cardiorespiratory adaptations is most evident at high doses (≈1 g/day) in older endurance-training cohorts, and is plausibly mediated by suppression of redox- and inflammation-driven training signals. At conservative doses (≤500 mg/day), the signal is weaker and inconsistent. Practical consideration: endurance-trained adults seeking cardiorespiratory adaptations may prefer ≤500 mg/day and dosing on rest days or away from the training window.

  • Stress management: Direction is indirect, plausibly mild positive via inflammation suppression. Trans-resveratrol does not act on the HPA (hypothalamic–pituitary–adrenal, the body’s primary stress-response axis) axis directly, and it does not substitute for behavioural stress management (sleep, breathing practices, exercise). Reductions in CRP and other inflammatory markers may support resilience to chronic-stress-related inflammatory load, particularly in adults with metabolic disease, though direct evidence on perceived-stress endpoints is limited.

Monitoring Protocol & Defining Success

Baseline laboratory and clinical measurements help identify adults most likely to benefit from trans-resveratrol and provide a reference for follow-up. A reasonable cadence is baseline, then 8–12 weeks after initiation, then every 6–12 months during continued use; adults on high-dose (>500 mg/day) protocols warrant additional liver-function checks at 8–12 weeks. Adults already taking interacting medications should follow their existing therapy-specific monitoring schedule (e.g., INR for warfarin) more closely after starting trans-resveratrol.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–85 mg/dL Tracks the population (diabetes/metabolic disease) where benefit is most evident Conventional reference 70–99 mg/dL; fasting required; pair with insulin
HbA1c <5.4% Average glucose over 2–3 months; primary glycemic outcome in trans-resveratrol diabetes trials Conventional cut-points: <5.7% normal; 5.7–6.4% prediabetic; ≥6.5% diabetic; non-fasting
Fasting insulin 2–6 µIU/mL Quantifies insulin resistance, which trans-resveratrol can modestly reduce in metabolic disease Conventional reference often up to 24.9 µIU/mL; combine with glucose for HOMA-IR (homeostatic model assessment of insulin resistance)
hs-CRP <0.8 mg/L Tracks systemic inflammation, the inflammatory endpoint where evidence is most consistent hs-CRP = high-sensitivity C-reactive protein; conventional reference <3.0 mg/L; avoid testing during acute illness
Lipid panel (LDL-C, HDL-C, triglycerides) LDL-C <100 mg/dL; HDL-C >50 mg/dL; triglycerides <100 mg/dL Cardiovascular risk markers; modest improvements reported in some trans-resveratrol trials LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; conventional LDL-C target <130 mg/dL; fasting preferred
Blood pressure <120/80 mmHg Captures the subgroup-dependent BP-lowering effect at ≥300 mg/day and in diabetes Conventional hypertension threshold ≥130/80 mmHg (ACC/AHA); home monitoring preferred; same time of day, seated, after rest
Flow-mediated dilation (FMD) >7% Direct measure of endothelial function — the most consistently improved trans-resveratrol endpoint Specialised vascular-lab ultrasound; not a routine primary-care test; improvement of approximately +1.4% pooled in trials
ALT, AST ALT <25 U/L; AST <25 U/L Detects hepatic-enzyme elevations reported at high trans-resveratrol doses ALT = alanine aminotransferase; AST = aspartate aminotransferase; conventional reference <35–40 U/L; especially relevant at >500 mg/day
eGFR >90 mL/min/1.73 m² Rules in/out renal impairment relevant to caution thresholds eGFR = estimated glomerular filtration rate; non-fasting; standard chemistry panel
INR (if on warfarin) Patient-specific therapeutic range Detects additive antiplatelet/anticoagulant effect INR = international normalized ratio; check more frequently after initiating or stopping trans-resveratrol

Qualitative markers to track:

  • Energy and exercise tolerance
  • Endurance training response (perceived improvement or plateau in cardiorespiratory adaptations, especially at higher doses)
  • Joint comfort and recovery from exercise
  • Subjective inflammation indicators (skin, sinuses, digestion)
  • Bleeding or bruising tendency, especially on antiplatelet/anticoagulant therapy
  • Gastrointestinal tolerance, particularly when changing dose or formulation

Emerging Research

  • NMN combination strategies: ongoing trials are examining trans-resveratrol combined with NAD+ precursors such as NMN and NR for cardiometabolic and cognitive endpoints, motivated by the hypothesis that SIRT1 activation requires adequate NAD+ availability. Outcomes from these trials will help test the synergy assumed in many longevity-stack protocols.

  • Polyphenol-combination prevention trials in cognition: the Phase 2 RQC (resveratrol, quercetin, curcumin) trial (NCT06470061) plans to enrol approximately 200 adults at risk of Alzheimer’s disease, using retinal amyloid-beta and cognitive endpoints. Results will inform whether multi-polyphenol combinations achieve effects that monotherapy has not.

  • Resveratrol with resistance training in sarcopenia: an ongoing trial (NCT06585865) combines 500 mg/day trans-resveratrol with resistance training in approximately 36 adults with anabolic resistance, measuring muscle mass and strength outcomes, plus circulating extracellular-vesicle microRNA profiles. This will test whether trans-resveratrol potentiates or interferes with resistance-training adaptations in older adults.

  • Polyphenol-stack chronic-illness trials: the Curcumin–Resveratrol–Stinging Nettle trial in Gulf War Illness (NCT05377242) is enrolling approximately 390 participants, evaluating polyphenol-combination effects on chronic-inflammation-driven physical and mental functioning measures.

  • Cardiometabolic mechanistic work: the Short Interval Resveratrol Trial in Cardiovascular Surgery (NCT03762096) tests trans-resveratrol’s effects on endothelial function in adults with type 2 diabetes and coronary artery disease, providing focused mechanistic data in a high-prior-probability population.

  • Foundational mechanism re-examination: the Mansouri et al. (2025) GRADE-assessed dose-response meta-analysis (Mansouri et al., 2025) directly questions whether oral trans-resveratrol meaningfully activates SIRT1 in humans at typical supplemental doses. Future research clarifying whether enhanced-bioavailability formulations close this translational gap, or whether trans-resveratrol’s clinical benefits operate primarily through SIRT1-independent mechanisms (eNOS, AMPK, antioxidant), will substantially shape the field’s posture either way.

  • Bioavailability and formulation science: active research on micronized, nano, phytosome, and prodrug strategies aims to raise sustained plasma trans-resveratrol concentrations into ranges where in vitro mechanistic effects might plausibly operate. Whether such formulations also raise the risk-side profile (drug interactions, exercise blunting) will be equally important.

Conclusion

Trans-resveratrol is the most-studied stilbene polyphenol in longevity science, yet the human clinical evidence is more modest than the laboratory work suggested it would be. The most consistently replicated benefits are improved endothelial function and reductions in markers of systemic inflammation, with meaningful effects on glycemic control concentrated in adults who already have type 2 diabetes or metabolic disease. Blood-pressure lowering appears restricted to higher doses or specific subgroups rather than the general user. Cancer prevention, cognitive protection, and direct lifespan extension remain unproven in human data, and the foundational hypothesis that oral trans-resveratrol meaningfully activates the proposed primary longevity target at human-achievable doses has been challenged by recent evidence — although enhanced-bioavailability strategies may yet alter that picture.

Bioavailability is the central practical limitation. Standard trans-resveratrol powder is poorly absorbed, and the formulation chosen substantially shapes whether plasma exposure reaches biologically relevant concentrations. Safety is generally favourable at conservative doses; the more notable concerns relate to drug-interaction potential, gastrointestinal tolerance and hepatic enzymes at very high doses, and an unresolved adaptation-blunting signal in endurance-trained populations.

For longevity-oriented adults already carrying cardiometabolic risk, trans-resveratrol at modest doses in an enhanced-bioavailability formulation has a defensible evidence-supported role. For metabolically healthy adults, the evidence base supports realistic, modest expectations rather than the foundational longevity narrative often associated with the compound.

Top - Benefits - Risks - Protocol